LMNL

Liminal BioSciences Inc. [LMNL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

LMNL Stock Summary

In the News

LMNL Financial details

Company Rating
-
Market Cap
27.62M
Income
354K
Revenue
492K
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
251
Optionable
No
Shortable
Yes
Earnings
07 Nov 2023
P/E
99.67
Forward P/E
-
PEG
-9.93
P/S
75.08
P/B
1.64
P/C
-
P/FCF
-1.02
Quick Ratio
2.18
Current Ratio
2.78
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0.06
EPS next Y
-
EPS next Q
-
EPS this Y
-37.62%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-66.94%
Revenue last 5Y
-61.49%
Revenue Q/Q
-17.65%
EPS Q/Q
19.51%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
-
Inst Trans
-
ROA
1%
ROE
1%
ROC
-1.5%
Gross Margin
100%
Oper. Margin
-6900%
Profit Margin
72%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.1-8.5
52W High
-
52W Low
-
RSI
-
Rel Volume
0.21
Avg Volume
23.73K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
29.3405
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-

Something similar

Top by Market Cap
AAPL
1YD.DE
0YXG.L
EMBASSY.NS
MSF.DE
Same Sector
BAFNAPH.NS
CTLT
3079.T
9989.HK
SGHT
Check Those
BWA
HDLB
2383.HK
3023.HK
000839.SZ
Similar Market Cap
TPMN
8420.HK
ULC.DE
SPI
2699.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 23.73K
  • Market Capitalization 27.62M
  • Employee 251
  • CEO Mr. Bruce Pritchard BA, CA, FIOD
  • Headquarters Laval,QC,CA
  • IPO Date 2009-12-18
  • Website https://www.liminalbiosciences.com

Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.